Tvardi Therapeutics is a Texas-based biopharmaceutical company developing a new class of small molecule medicines designed to treat diverse cancers, chronic inflammatory diseases, and fibrotic diseases by inhibiting the STAT3 regulatory protein. Its leading drug candidate is in the clinical stage.